{"id":42127,"date":"2025-09-23T16:37:13","date_gmt":"2025-09-23T08:37:13","guid":{"rendered":"https:\/\/flcube.com\/?p=42127"},"modified":"2025-09-23T16:37:14","modified_gmt":"2025-09-23T08:37:14","slug":"stealth-biotherapeutics-receives-fda-accelerated-approval-for-forzinity-in-barth-syndrome","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42127","title":{"rendered":"Stealth BioTherapeutics Receives FDA Accelerated Approval for Forzinity in Barth Syndrome"},"content":{"rendered":"\n

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Stealth BioTherapeutics\u2019 Forzinity (elamipretide) injection<\/strong>, the first treatment approved for Barth syndrome<\/strong> in patients weighing at least 30\u202fkg. Barth syndrome, a rare X\u2011linked mitochondrial disorder, predominantly affects males and often presents with severe infantile heart failure, leading to premature mortality. Adults who survive into adolescence frequently suffer chronic fatigue, impaired stamina, and exercise intolerance, profoundly diminishing quality of life.<\/p>\n\n\n\n

How Forzinity Works<\/h3>\n\n\n\n

Forzinity targets the inner mitochondrial membrane<\/strong>, restoring mitochondrial ultrastructure and enhancing bioenergetic function. The accelerated approval hinged on a statistically significant improvement in knee extensor muscle strength<\/strong>\u2014the pivotal muscle used to straighten the knee. The FDA judged this gain as \u201creasonably likely to predict\u201d<\/strong> meaningful clinical benefits such as easier standing and increased walking distance.<\/p>\n\n\n\n

Post\u2011Approval Commitments<\/h3>\n\n\n\n

Under the accelerated approval pathway, Stealth BioTherapeutics must conduct a post\u2011approval, randomized, double\u2011blind, placebo\u2011controlled trial<\/strong> to confirm that the observed muscle\u2010strength gains translate into real\u2011world benefits for Barth syndrome patients.<\/p>\n\n\n\n

Market and Therapeutic Impact<\/h3>\n\n\n\n